MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--In response to surging veterinary demand for personalized canine cancer testing, ImpriMed, a leading precision medicine startup focused on leveraging artificial intelligence to improve cancer treatment, today announced the launch of ImpriMed Drug Response Predictions (DRP). Augmenting the company’s flagship Personalized Prediction Profile service, DRP is now being offered as a standalone test to meet veterinary calls for accessible, cost-effective precision medicine at scale. DRP empowers veterinarians with AI-driven clinical outcome predictions for canines with lymphoma and leukemia tailored to individual patient needs, improving efficacy and accelerating patient treatment.
Precision diagnostics enable patient-specific cancer therapies upfront, eliminating the need for costly and time-consuming wait-and-see approaches after drug administrations. ImpriMed’s DRP is a first-of-its-kind capability that uses AI models trained on extensive, clinically proven data sources to make personalized treatment predictions for canine cancer. The service employs a proprietary drug sensitivity test that analyzes the efficacy of up to 13 of the most prescribed blood cancer drugs on patients’ living cells. CHOP prognostic and single-drug response predictions are provided within six to seven calendar days upon receipt of patient samples at ImpriMed’s California laboratory. Widely considered the gold-standard treatment for canine lymphoma, CHOP is a first-line, multi-agent chemotherapy protocol that uses four different drugs – cyclophosphamide, doxorubicin, vincristine, and prednisone – to tackle cancer from multiple directions, increasing the chances of remission.
"AI is a powerful ally in advancing patient outcomes, enhancing diagnostic accuracy, optimizing treatments, and ultimately, elevating the standard of care,” said Sungwon Lim, ImpriMed’s CEO and co-founder. “We’re thrilled to unveil ImpriMed Drug Response Predictions to fulfill growing customer demand for individualized testing and fundamentally transform clinical approaches to canine cancer treatment. With ImpriMed’s personalized predictions, veterinarians can quickly and confidently establish treatment plans that improve the quality of life for patients and their pet parents.”
AI-Driven Precision Provides Promising Results
ImpriMed’s groundbreaking application of AI technology to personalized medicine has already yielded impressive results, including:
- Extended Canine Median Survival Time: Dogs with relapsed B-cell lymphoma that received ImpriMed's AI-driven predictions experienced an extended median survival time of 160 to 187 days, as published in Frontiers in Oncology.
- Improved Veterinarian-Client Relationships: 80 percent of surveyed veterinary oncologists (70 out of 87) reported positive client reactions to ImpriMed, citing a better understanding of treatment options through the personalized care plans highlighted in ImpriMed reports. By expediting access to the most effective treatments, ImpriMed may help reduce client expenses and potentially improve patient outcomes and overall well-being.
- Recommended by Veterinarians: 95 percent of surveyed veterinary oncologists (83 out of 87) using ImpriMed were satisfied with both the company’s report content and ImpriMed’s services overall. Survey respondents noted decreased treatment costs, improved clinician or facility/clinic reputation, and the potential to improve patient survival time as primary service benefits.
To date, ImpriMed has provided veterinary precision medicine services to more than 6,000 dogs with lymphoma or leukemia and is now poised to expand its footprint with its DRP launch. This service provides an accessible entry point for veterinarians to leverage the company's cutting-edge technology while advancing ImpriMed’s proprietary clinical data set, broadening oncological innovation and scalability to human applications.
For more information about ImpriMed’s Drug Response Predictions service, please visit https://imprimedicine.com/drug-response-predictions.
About ImpriMed
ImpriMed, founded in 2017 in Silicon Valley, is a leading precision medicine startup revolutionizing cancer treatment with artificial intelligence. The company’s pioneering drug response prediction technology helps reduce costs, accelerate treatment, enhance efficacy, and improve the quality of life for patients. To date, ImpriMed’s technology has been deployed across more than 40 U.S. states, Canada, England, and France, treating 6,500+ canine and feline blood cancer patients as of 2024. ImpriMed is redefining the future of oncology treatment with personalized, effective solutions. For additional information, visit www.imprimedicine.com.
